Shield Therapeutics (LSE:STX) Total Liabilities : £14.57 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Total Liabilities?

Shield Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was £14.57 Mil.

Shield Therapeutics's quarterly Total Liabilities increased from Jun. 2022 (£3.25 Mil) to Dec. 2022 (£16.65 Mil) but then declined from Dec. 2022 (£16.65 Mil) to Jun. 2023 (£14.57 Mil).

Shield Therapeutics's annual Total Liabilities increased from Dec. 2020 (£2.25 Mil) to Dec. 2021 (£3.72 Mil) and increased from Dec. 2021 (£3.72 Mil) to Dec. 2022 (£16.65 Mil).

Shield Therapeutics Total Liabilities Historical Data

The historical data trend for Shield Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Total Liabilities Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

3.10

4.17

2.25

3.72

16.65

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial													1.39	3.72	3.25	16.65	14.57

Shield Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shield Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.639	+	(6.008	+	-8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	16.65

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	22.074	-	5.427
	=	16.65

Shield Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.86	+	(5.705	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	14.57

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	41.667	-	27.102
	=	14.57

Shield Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.